solute carrier family 7 member 5Genealiases: 4F2LC · CD98 · D16S469E · E16 · LAT1 · MPE16
Q-omics provides the consensus-scored SLC7A5 profile across patient tissues and cancer cell-line models. SLC7A5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC7A5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SLC7A5 protein abundance shows 34,480 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where SLC7A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A5 survival associations across molecular data types. SLC7A5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A5 RNA expression–survival associations across cancer types. High SLC7A5 expression shows unfavorable associations in KIRC, KIRP, MESO, HNSC and BRCA, but favorable associations in UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC7A5 RNA expression.
This table summarizes SLC7A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC7A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A5 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LUAD, LUSC and READ. The COAD box plot shows higher SLC7A5 RNA expression in tumor versus normal tissue (log2 FC = +4.091, t-test p < 0.001).
This table shows molecular features associated with SLC7A5 in patient tissues and cancer cell lines. In patient samples, SLC7A5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
